[go: up one dir, main page]

EP2869821A4 - Compositions and methods for treating and inhibiting viral infections - Google Patents

Compositions and methods for treating and inhibiting viral infections

Info

Publication number
EP2869821A4
EP2869821A4 EP13813787.2A EP13813787A EP2869821A4 EP 2869821 A4 EP2869821 A4 EP 2869821A4 EP 13813787 A EP13813787 A EP 13813787A EP 2869821 A4 EP2869821 A4 EP 2869821A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
methods
viral infections
inhibiting viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13813787.2A
Other languages
German (de)
French (fr)
Other versions
EP2869821A2 (en
Inventor
Justice E Obi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRACELAND BIOTECHNOLOGY CATALYST, LLC
Original Assignee
GRACELAND BIOTECHNOLOGY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/540,749 external-priority patent/US20140011837A1/en
Priority claimed from US13/687,273 external-priority patent/US20140011838A1/en
Priority claimed from US13/932,445 external-priority patent/US20140011839A1/en
Application filed by GRACELAND BIOTECHNOLOGY Inc filed Critical GRACELAND BIOTECHNOLOGY Inc
Publication of EP2869821A2 publication Critical patent/EP2869821A2/en
Publication of EP2869821A4 publication Critical patent/EP2869821A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP13813787.2A 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections Withdrawn EP2869821A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/540,749 US20140011837A1 (en) 2012-07-03 2012-07-03 Compositions and methods for treating warts associated with viral infections
US13/687,273 US20140011838A1 (en) 2012-07-03 2012-11-28 Compositions and methods for treating warts associated with viral infections
US13/932,445 US20140011839A1 (en) 2012-07-03 2013-07-01 Compositions and methods for treating and inhibiting viral infections
PCT/US2013/049046 WO2014008248A2 (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections

Publications (2)

Publication Number Publication Date
EP2869821A2 EP2869821A2 (en) 2015-05-13
EP2869821A4 true EP2869821A4 (en) 2016-04-06

Family

ID=49882589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13813787.2A Withdrawn EP2869821A4 (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections

Country Status (4)

Country Link
EP (1) EP2869821A4 (en)
CN (1) CN104703601A (en)
CA (1) CA2927146A1 (en)
WO (1) WO2014008248A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544153B1 (en) 2014-02-24 2016-06-06 Ntd Labs, S.L. Use of a casein hydrolyzate as an antiviral agent
CN104352495A (en) * 2014-11-15 2015-02-18 广州凯普生物科技有限公司 Medicine for treating wart diseases
JP7176767B2 (en) * 2017-04-13 2022-11-22 国立大学法人 鹿児島大学 Novel amodiaquine analogues and methods of use thereof
MX2021001502A (en) 2018-08-06 2021-07-15 Nielsen Biosciences Inc TREATMENT OF WARTS.
CN109288816B (en) * 2018-12-04 2019-11-22 广州凯普医药科技有限公司 A kind of chloroquine gel and its preparation method and application
CN110917196B (en) * 2020-02-05 2020-06-05 广州康健医学科技有限公司 Chloroquine antibacterial disinfectant and application thereof
CN112089841A (en) * 2020-04-05 2020-12-18 徐静 Pharmaceutical composition for treating diseases caused by virus infection of epithelial tissues
US20230123388A1 (en) * 2020-04-14 2023-04-20 Glanis Pharmaceuticals, Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
CN114848642A (en) * 2022-07-07 2022-08-05 广州康健医学科技有限公司 Application of chloroquine phosphate in preparation of medicine for preventing and treating high-risk HPV infection, cervical cancer precursor lesion and cervical cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747407B2 (en) * 1998-04-14 2002-05-16 Bioagency Ag Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
CA2687964A1 (en) * 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACOBS P H ET AL: "Effect of chloroquine anb placebo on warts", ARCHIVES OF DERMATOLOGY, AMERICAN MEDICAL ASSOCIATION, US, vol. 87, no. 1, 1 January 1963 (1963-01-01), pages 89 - 90, XP009188564, ISSN: 0003-987X *
MURPHY J C ET AL: "Chloroquine treatment of warts. A double-blind clinical study", ROCKY MOUNTAIN MEDICAL JOURNAL, COLORADO MEDICAL SOCIETY, DENVER, CO, US, vol. 62, no. 1, 1 January 1965 (1965-01-01), pages 25 - 26, XP009188565, ISSN: 0035-760X *
ZABEL H ET AL: "Sensitization to light during chloroquine diphosphate therapy", ZEITSCHRIFT FUER HAUT UND GESCHLECHTSKRANKHEITEN, GROSSE, BERLIN, DE, vol. 29, no. 7, 1 January 1960 (1960-01-01), pages 203 - 206, XP009188566, ISSN: 0044-2844 *

Also Published As

Publication number Publication date
CN104703601A (en) 2015-06-10
CA2927146A1 (en) 2014-01-09
WO2014008248A3 (en) 2014-02-27
EP2869821A2 (en) 2015-05-13
WO2014008248A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
IL277196B (en) Methods and compositions for genome engineering
IL238416A0 (en) Compositions and methods for treating proteinopathies
AP3269A (en) Methods and compounds for treating paramyxoviridaevirus infections
PL2925888T3 (en) Compositions and methods for treating cancer
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
SG11201507507PA (en) Compositions and methods for treating mpsi
DK3292875T3 (en) Compositions and methods for treating diseases
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
EP2817018A4 (en) Methods and compositions for preventing or treating ophthalmic conditions
EP2869821A4 (en) Compositions and methods for treating and inhibiting viral infections
IL234829A0 (en) Methods and compositions for treating inflammation
IL233968A (en) Compounds and compositions comprising them for treating fibrosis
ZA201503474B (en) Compositions and methods for treating bacterial infections
EP2624841A4 (en) Compositions for treating chronic viral infections
ZA201501601B (en) Virus purification and formulation process
IL238403A0 (en) Methods and compositions for treating progesterone-dependent conditions
PL2838903T3 (en) Methods and compositions for treating viral infections
EP2887967A4 (en) Compositions and methods for treating hepatocellular cancer
EP2838526A4 (en) Materials and methods for prevention and treatment of viral infections
SG11201402899TA (en) Methods and compositions for treating viral diseases
EP2841102A4 (en) Methods and compositions for treating cancer
ZA201308683B (en) Methods and compositions suitable for preventing and treating hyperleptinemia
GB201222736D0 (en) Composition and process
AU2012905097A0 (en) Agents and methods for inhibiting virus infection
EP2747765A4 (en) Compositions and methods for treating viral diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/20 20060101ALI20160229BHEP

Ipc: A61K 31/4706 20060101AFI20160229BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GRACELAND BIOTECHNOLOGY CATALYST, LLC

Owner name: OBI, JUSTICE E.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201